Clinical Trial: Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07866066) titled 'Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes' on Oct. 05.

Brief Summary: The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

Study Start Date: Nov. 02

Study Type: INTERVENTIONAL

Condition: Diabetes Mellitus, Type 2

Intervention: DRUG: Maridebart cafraglutide

Administered subcutaneously.

DRUG: Semaglutide

Administered subcutaneously.

Recruitment Status: N...